Advances in clinical trials of Ebola vaccine
ZHANG Zhe
HOU Li-hua
Abstract：Ebola virus disease (EVD) is a high fatality hemorrhagic fever disease caused by Ebola virus. Worldwide attention has been attracted due to the large-scale Ebola outbreak in recent years. Currently, many types of Ebola vaccines have been evaluated in the clinical trials. Viral vector vaccines are impressive owing to its fast and high-level immune response. Among them, recombinant vesicular stomatitis virus-based vaccine expressing Zaire Ebola virus glycoprotein (rVSV-ZEBOV) has showed a significant protection against EVD in a phase Ⅲ clinical trial in Guinea. This paper aims to review Ebola vaccines in the undergoing clinical trials and focus on rVSV-ZEBOV in terms of safety and immunogenicity.
Keywords：Ebola vaccineviral vector vaccineclinical trialrVSV-ZEBOV
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 430-435,465 )